Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: \textscLong\textsc-\textscTerm Results of Two Phase \textscIII Randomized Controlled Trials - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Arthritis Care & Research Année : 2022

Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: \textscLong\textsc-\textscTerm Results of Two Phase \textscIII Randomized Controlled Trials

Dates et versions

hal-03894180 , version 1 (12-12-2022)

Identifiants

Citer

Tore K. Kvien, Philip G. Conaghan, Laure Gossec, Vibeke Strand, Mikkel Østergaard, et al.. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: \textscLong\textsc-\textscTerm Results of Two Phase \textscIII Randomized Controlled Trials. Arthritis Care & Research, 2022, 74 (5), pp.759--767. ⟨10.1002/acr.24517⟩. ⟨hal-03894180⟩
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More